Bionano Genomics (BNGO) stock tumbled 5.02% in intraday trading on Friday, as investors reacted to an earnings preview that projected losses and a significant drop in revenue for the company's upcoming financial report.
According to the earnings preview, Bionano Genomics, based in San Diego, California, is expected to report a 42.2% decrease in revenue to $6.2 million for the quarter ending December 31, 2024, compared to $10.72 million in the same period a year ago. The mean estimate from analysts suggests the company will post a loss of $6.00 per share.
The bearish sentiment surrounding Bionano Genomics' earnings prospects appears to have weighed heavily on the stock's performance. With analysts maintaining a "hold" rating on the shares and a median 12-month price target of $60.00, investors may be exercising caution ahead of the company's financial results release, scheduled for March 3, 2025 (estimated).
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。